Difference between revisions of "Etranacogene dezaparvovec (Hemgenix)"
Jump to navigation
Jump to search
(Created page with "==History of changes in EMA indication== *2/20/2023: Granted conditional authorisation for the treatment of severe and moderately severe Haemophilia B (congenital Factor IX de...") |
m |
||
| Line 2: | Line 2: | ||
*2/20/2023: Granted conditional authorisation for the treatment of severe and moderately severe Haemophilia B (congenital Factor IX deficiency) in adult patients without a history of Factor IX inhibitors. | *2/20/2023: Granted conditional authorisation for the treatment of severe and moderately severe Haemophilia B (congenital Factor IX deficiency) in adult patients without a history of Factor IX inhibitors. | ||
| + | [[Category:Drugs]] | ||
[[Category:Stub]] | [[Category:Stub]] | ||
[[Category:EMA approved in 2023]] | [[Category:EMA approved in 2023]] | ||
Revision as of 18:24, 24 March 2023
History of changes in EMA indication
- 2/20/2023: Granted conditional authorisation for the treatment of severe and moderately severe Haemophilia B (congenital Factor IX deficiency) in adult patients without a history of Factor IX inhibitors.